WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

It also suppresses appetite and boosts feelings of fullness, which can then lead to reduced food intake and potential weight loss. Ozempic, Wegovy, and compounded semaglutide are once-weekly ...

"Results from STEP UP further strengthen the clinical profile of semaglutide ... in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss.

“It’s actually a very reassuring safety profile.” With what’s known now, the three doctors say they’re comfortable prescribing semaglutide long-term for weight loss for a patient ...

Research is still evolving to identify all the ways semaglutide can affect your overall health. Even so, it probably makes ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth ... by the weight-loss profile of CagriSema." ...

RANI READ THE FULL RANI RESEARCH REPORT On February 5th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shared its preclinical readout from the RT-116 study demonstrating successful oral delivery of ...